Abstract: Anti-malware process protection techniques are described. In one or more implementations, an anti-malware process is launched. The anti-malware process is verified based at least in part on an anti-malware driver that contains certificates which contain an identity that is signed with the trusted certificate from a verified source. After the anti-malware process is verified, the anti-malware process may be assigned a protection level, and an administrative user may be prevented from altering the anti-malware process.

Abstract: Anti-malware process protection techniques are described. In one or more implementations, an anti-malware driver is signed using a hash that identifies a manufacturer of the anti-malware driver. The anti-malware driver is then provided to a computing device. The anti-malware driver may be assigned a protection level based on an agreement between the anti-malware manufacturer and an operating system manufacturer, and this protection level effects the operation of the anti-malware program on the computing device.

Abstract: Certification of a key, which a Trusted Platform Module (TPM) has attested as being non-migratable, can be performed in a single round trip between the certificate authority (CA) and the client that requests the certificate. The client creates a certificate request, and then has the TPM create an attestation identity key (AIK) that is bound to the certificate request. The client then asks the TPM to sign the new key as an attestation of non-migratability. The client then sends the certificate request, along with the attestation of non-migratability to the CA. The CA examines the certificate request and attestation of non-migratability. However, since the CA does not know whether the attestation has been made by a trusted TPM, it certifies the key but includes, in the certificate, an encrypted signature that can only be decrypted using the endorsement key of the trusted TPM.

Abstract: In a pre-operating system environment on a device prior to loading and running an operating system on the device, a policy identifying configuration settings for the operating system is obtained. The operating system itself is prevented from changing this policy, but the policy can be changed under certain circumstances by components of the pre-operating system environment. The policy is compared to configuration values used by the operating system, and the operating system is allowed to boot with the configuration values if the configuration values satisfy the policy. However, if the configuration values do not satisfy the policy, then a responsive action is taken.

Abstract: Certification of a key, which a Trusted Platform Module (TPM) has attested as being non-migratable, can be performed in a single round trip between the certificate authority (CA) and the client that requests the certificate. The client creates a certificate request, and then has the TPM create an attestation identity key (AIK) that is bound to the certificate request. The client then asks the TPM to sign the new key as an attestation of non-migratability. The client then sends the certificate request, along with the attestation of non-migratability to the CA. The CA examines the certificate request and attestation of non-migratability. However, since the CA does not know whether the attestation has been made by a trusted TPM, it certifies the key but includes, in the certificate, an encrypted signature that can only be decrypted using the endorsement key of the trusted TPM.

Abstract: A front-end system accepts samples and selectively provides aliquots of those samples to selected clinical chemistry analyzers coupled to the front-end system. The front-end system is coupled to an assembly of one or more clinical chemistry analyzers that might, for example, provide complementary analytical tools so that the overall system of front-end system and clinical chemistry analyzers provides a predetermined broad range of clinical analytical testing. The testing protocols for samples input to the overall system can be independently determined. Any sample may undergo a test within one or more of the clinical chemistry analyzers or a series of tests within a single or more typically within plural ones of the analyzers, depending upon the testing sequence defined in for that sample. The front-end system automatically identifies samples, draws aliquots, and transports the aliquots to the one or more clinical chemistry analyzers coupled to the front-end system.

Abstract: A truck for preventing damage thereto when attached to a skate board and negotiating and contacting a curb. A body attaches to the skate board and an axle extends rotatably through the body and terminates in a pair of wheels, respectively. A roller is rotatably positioned in the body and has the axle extend rotatably therethrough so as to prevent damage to the axle when the truck negotiates and contacts the curb, by virtue of the roller contacting the curb and rotating relative to the axle as the truck negotiates the curb.

Abstract: An article comprising a substrate, and a textured, matte-finish, low adhesion backsize coating on one surface of the substrate, wherein the coating comprises polyvinyl carbamate having nitrogen-bonded hydrocarbon side chains which provide terminal alkyl groups more than five carbons in length.

Abstract: A process employing a supercritical fluid anti-solvent for sizing prednisolone acetate is disclosed. The process optionally incorporates sterilization filters. Average particle sizes of about 1 .mu.m or less (number average) and narrow particle size ranges are obtainable. The process comprises the steps of (a) forming a solution by dissolving prednisolone acetate in acetone such that the concentration of prednisolone acetate is approximately 80% or less of its solubility in acetone; and (b) transporting the solution formed in step (a) through an orifice having a diameter of 50-100 .mu.m into a mixer/expander containing compressed CO.sub.2, wherein the compressed CO.sub.2 is at a temperature from about 40.degree. to 80.degree. C. and has a density less than the density of the solution by at least 0.3 g/cc, to expand the solution so that the acetone dissolves in the CO.sub.2 and the prednisolone acetate precipitates.

Abstract: A method of reducing metal oxides comprises introducing feedstock material into a plasma torch reactor according to two different flow patterns. A primary feedstock is fed into the immediate vicinity of the plasma stream in a helical pattern surrounding the plasma stream. The primary feedstock material preferably comprises the metal oxides to be reduced within the reactor. A secondary feedstock material is fed at a more remote location, preferably in a flow pattern developing a protective wall for the inside of the reactor. A preferred assembly is provided for application of the process. For the preferred embodiment, the assembly comprises a top plate, a central ramp, a bottom plate and a liner to form separate feed channels for the primary and secondary feedstock.